Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL613508 Target Snapshot

DU-145 · CELL-LINE · Homo sapiens

44,268Compounds
4,098Assays
82Approved Drugs
9,237.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DU-145 as ChEMBL target CHEMBL613508. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DU-145
CELL-LINE · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL613508
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether DU-145 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDU-145
UniProt AccessionN/A

DU-145

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as DU-145.

Review nameDU-145
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

82
Approved
30
Phase III
40
Phase II
14
Phase I
Assay Mix

Activity Type Distribution

IC509,031.0
EC50206.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1808826 10.37 IC50 0.043 Preclinical
CHEMBL159 10.2 IC50 0.063 Approved
CHEMBL92 10.0 IC50 0.1 Approved
CHEMBL269081 9.96 IC50 0.11 Preclinical
CHEMBL1808824 9.8 IC50 0.16 Preclinical
CHEMBL1808829 9.62 IC50 0.24 Preclinical
CHEMBL1288638 9.52 IC50 0.3 Preclinical
CHEMBL1808822 9.52 IC50 0.3 Preclinical
CHEMBL554604 9.49 IC50 0.32 Preclinical
CHEMBL5206589 9.48 IC50 0.33 Preclinical
Distribution

pChEMBL Value Distribution

1383
5.0
991
5.5
557
6.0
293
6.5
276
7.0
129
7.5
98
8.0
26
8.5
21
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
AFATINIB
CHEMBL1173655
Approved 2013
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
VORINOSTAT
CHEMBL98
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
TOPOTECAN
CHEMBL84
Approved 1996
IRINOTECAN
CHEMBL481
Approved 1996
GEMCITABINE
CHEMBL888
Approved 1996
DOCETAXEL ANHYDROUS
CHEMBL92
Approved 1995
DOCETAXEL
CHEMBL3545252
Approved 1995
VINORELBINE
CHEMBL553025
Approved 1994
PACLITAXEL
CHEMBL428647
Approved 1992
PODOFILOX
CHEMBL61
Approved 1990
MITOXANTRONE
CHEMBL58
Approved 1987
AMSACRINE
CHEMBL43
Approved 1987
ETOPOSIDE
CHEMBL44657
Approved 1983
NICLOSAMIDE
CHEMBL1448
Approved 1982
DIGITOXIN
CHEMBL254219
Approved 1982
MITOMYCIN
CHEMBL105
Approved 1981
DAUNORUBICIN
CHEMBL178
Approved 1979
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
DOXORUBICIN
CHEMBL53463
Approved 1974
VINBLASTINE
CHEMBL159
Approved 1965
DACTINOMYCIN
CHEMBL1554
Approved 1964
VINCRISTINE SULFATE
CHEMBL501867
Approved 1963
VINCRISTINE
CHEMBL90555
Approved 1963
FLUOROURACIL
CHEMBL185
Approved 1962
COLCHICINE
CHEMBL107
Approved 1961
METHOTREXATE
CHEMBL34259
Approved 1953
Assay Landscape

Assay Landscape

4,100
Total Assays
6,249
Tested Compounds
4
Assay Types
Functional — 3,984 assays, 6,249 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3,868 6,247 5.4
organism-based format 116 2 6.1
ADME — 109 assays, 22 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 109 22 4.9
Toxicity — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 0
Unassigned — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine